News | News By Subject | News by Disease News By Date | Search News

Cystic fibrosis News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Vertex Pharmaceuticals (MA) Surges As FDA Advisory Panel Approves Kalydeco's Label Expansion     10/22/2014
InterMune, Inc. Goes Up On The Block; GlaxoSmithKline, Roche, Sanofi (France) Line Up     8/18/2014
Vertex Pharmaceuticals (MA) Grabs EU Recommendation For KALYDECO™ (Ivacaftor) In Eight Non-G551D Gating Mutations     6/27/2014
Vertex Pharmaceuticals (MA) Rockets As Cystic Fibrosis Combo Succeeds In Two Late Stage Trials     6/25/2014
Vertex Pharmaceuticals (MA) Trial Suggests Kalydeco May Work In More Cystic Fibrosis Patients     6/5/2014
Vertex Pharmaceuticals (MA) Reports Positive Ivacaftor Study Data, Plans To Initiate Larger Phase 3 Study     6/4/2014
One-Time Hepatitis C King Vertex Pharmaceuticals (MA) Shows Off Promising Phase 2 Cystic Fibrosis Data     5/5/2014
FDA Approves Vertex Pharmaceuticals (MA)'s KALYDECO™ (Ivacaftor) For Use In Eight Additional Mutations That Cause Cystic Fibrosis     2/24/2014
Vertex Pharmaceuticals (MA)'s Cystic Fibrosis Drug Ivacaftor Misses Goal In Late-Stage Study But Helps Some Adults     12/20/2013
AbbVie, Galapagos NV Ink $405 Million Cystic Fibrosis Pact     9/24/2013
Vertex Pharmaceuticals (MA) Shares Rocket as CF Drug Impresses in Phase 3 Study     8/1/2013
Insmed Incorporated Lung Antibiotic Passes Test But Falls Short of Investor Expectations     7/2/2013
These Mutated Cystic Fibrosis Cells are Worth Billions to Vertex Pharmaceuticals (MA)     6/17/2013
Vertex Pharmaceuticals Incorporated Booms on Cystic Fibrosis Combo Drug Study     4/23/2013
FDA Rejects Pharmaxis Ltd Drug Push Bid     3/19/2013

Featured Stories
University of Pittsburgh-Led Study Suggests Cystic Fibrosis Is Two Diseases, One Doesn’t Affect Lungs     7/23/2014
Cystic Fibrosis And Diabetes Link Explained, Lund University Study     6/3/2014
New Drug Target Found for Cystic Fibrosis Lung Disease, BC Children's Hospital Study     11/8/2012
Sea Sponge Chemical Fixes Cystic Fibrosis Defect, McGill University Study     10/29/2012
Differences Seen in Lung Microbes of Cystic Fibrosis Patients, Stanford University Study     10/1/2012
Big Advance Against Cystic Fibrosis: Stem Cell Researchers Create Lung Surface Tissue in a Dish, Massachusetts General Hospital Study     4/6/2012
Student, 16, Invents New Drug Cocktail to Fight Cystic Fibrosis, Wins Canadian Biotech Challenge, National Research Council of Canada laboratories Reveals     5/12/2011
Cystic Fibrosis Patients May Benefit From Combination Therapy Which Provides Hope For Cure Of Dangerous Infections, McMaster University Study     4/25/2011
New Cystic Fibrosis Drug Improves Lung Function, University of Colorado Study     12/22/2010
Novel Drug Aids CF Kids' Lungs, University of Colorado Study     12/20/2010
Drug Corrects CF Genetic Defect, University of Colorado Reveals     11/18/2010
TOBI Reduces Mortality in Patients with Cystic Fibrosis, Pa Lung Infection, Children's Hospital Boston Study     10/22/2010
One Step Closer to a Drug Treatment for Cystic Fibrosis, University of Missouri Professor Says     10/12/2010
Growth Hormone May Benefit Lungs in CF, University of Connecticut/Hartford Hospital Evidence-Based Practice Center Study     10/7/2010
MP-376 Safe and Effective for Treatment of P. Aeruginosa in CF Patients, University of California, San Diego (UCSD) Study Finds     5/17/2010

More News
Vertex Pharmaceuticals (MA) (VRTX) Reviews Recent Progress And Announces Upcoming Milestones In The Development Of Multiple Combinations Of Medicines That Target The Underlying Cause Of Cystic Fibrosis     10/9/2014
NovaBiotics Ltd Receives Orphan Drug Status From FDA For Lynovex® For The Treatment Of Cystic Fibrosis     9/16/2014
Parion Sciences Announces $3 Million Award From Cystic Fibrosis Foundation Therapeutics, Inc. To Accelerate The Development Of Novel CF Treatment     9/16/2014
AbbVie (ABBV) Cystic Fibrosis Scholarship Program Awards 40 Student Scholars With Annual Academic Awards     8/18/2014
AbbVie (ABBV) And Cystic Fibrosis Research, Inc. (CFRI) Team Up To Raise Awareness Of The Nutritional Needs Of CF Patients Through The Cfchef Shares Program     8/1/2014
Cystic Fibrosis Foundation Applauds Successful Phase 3 Results Of Ivacaftor (Kalydeco™) And Lumacaftor (VX-809) Drug Combination For People With Two Copies Of F508del Mutation Of Cystic Fibrosis     6/24/2014
Vertex Pharmaceuticals (MA) (VRTX) Announces Presentation Of New KALYDECO™ (Ivacaftor) Data At European Cystic Fibrosis Society Conference     6/12/2014
Aradigm Corporation (ARDM) Receives $5 Million Milestone For Dosing Of The First Patient In Phase 3 Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis     6/3/2014
PTC Therapeutics, Inc. (PTCT) Release: Ataluren Phase 3 Trial Results In Nonsense Mutation Cystic Fibrosis Published In The Lancet Respiratory Medicine     5/16/2014
Rehmann’s 16th Annual Chef’s Fantasy Dinner and Auction” Benefitting the Cystic Fibrosis Foundation Held in Cleveland     5/5/2014
Vertex Pharmaceuticals (MA) (VRTX) Release: Addition Of VX-661 To KALYDECO® (Ivacaftor) Improves Lung Function In People With CF Who Are Heterozygous For The F508del And G551D Mutations In 28-Day Phase 2 Proof-Of-Concept Study     5/2/2014
FDA Grants Orphan Drug Designation For Bayer HealthCare (BAY)'s Investigational Ciprofloxacin DPI (Dry Powder For Inhalation) For Treatment Of Non-Cystic Fibrosis Bronchiectasis     4/23/2014
Xenetic Biosciences Announces Positive Phase 1 Clinical Data For Pulmoxen™ For Treatment Of Cystic Fibrosis     4/7/2014
Proteostasis Therapeutics, Inc. Announces Extension Of Funded Collaboration With Cystic Fibrosis Foundation Therapeutics, Inc. For Novel Therapies Targeting Most Common CF Mutation     3/4/2014
Galapagos NV (GLPG.BR) Receives EU2.9 Million IWT Grant For Cystic Fibrosis Research     1/13/2014